Annual Report to Shareholders
IBD is a US$15.9 billion market. The current treatment approach to IBD is to suppress the inflammation with the goal of inducing and maintaining remission, while in the case of IBS, gastroenterologists primarily treat the symptoms of abdominal pain, bloating and alternating constipation and diarrhoea. These therapeutic approaches have high treatment failure rates. Consequently, there is a significant unmet medical need for products that can i) re-establish the homeostasis of the microbiome, ii) treat the inflammation and iii) repair the mucosal damage which will in turn have the downstream effect of reducing disease-associated diarrhoea.
Significant market opportunity
GI disorders affect a significant proportion of the population at some stage of their life, with IBS the most commonly diagnosed gastrointestinal condition, affecting an estimated 11% of the global population. IBD is a global disease with accelerating incidence in newly industrialised countries, with more than 5 million sufferers globally.
To view the Annual report, please visit:
About Anatara Lifesciences Ltd
Anatara Lifesciences (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. For more information, please visit www.anataralifesciences.com.
Anatara Lifesciences Ltd